Shopping Cart
- Remove All
- Your shopping cart is currently empty
Lucerastat(NBDGJ) is an orally available inhibitor of Glucosylceramide Synthase (GCS) with therapeutic potential for Fabry disease. GCS is a key enzyme in sphingolipid synthesis and inhibition of its activity reduces the accumulation of harmful substrates.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $766 | 6-8 weeks | |
50 mg | $995 | 6-8 weeks | |
100 mg | $1,760 | 6-8 weeks |
Description | Lucerastat(NBDGJ) is an orally available inhibitor of Glucosylceramide Synthase (GCS) with therapeutic potential for Fabry disease. GCS is a key enzyme in sphingolipid synthesis and inhibition of its activity reduces the accumulation of harmful substrates. |
Alias | OGT 923, NBDGJ, NB DGJ, N-(n-Butyl)deoxygalactonojirimycin, ACT 434964 |
Molecular Weight | 219.28 |
Formula | C10H21NO4 |
Cas No. | 141206-42-0 |
Smiles | C(CCC)N1[C@H](CO)[C@H](O)[C@H](O)[C@@H](O)C1 |
Relative Density. | 1.234 g/cm3 (Predicted) |
Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 20 mg/mL (91.21 mM), Sonication is recommended. H2O: 20 mg/mL (91.21 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO/H2O
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.